Clinical trials: Orbitopathy, Graves
Graves´ Disease
Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)
AGO study - adjuvant treatment, with NSAID, of endocrine ophthalmopathy in Graves´ disease Background - Already at diagnosis of Graves disease approximately 98% of the patients have morphological changes of the retrobulbar tissue…
- Trial name
- aGO (NCT01458600)
- Testing
- Diclofenac, Methimazole, L-thyroxin
- Where
- 3 sites in Sweden
- Volunteers
- 65 people
- Sponsor
- Mikael Lantz
Graves' Ophthalmopathy, Hypercholesterolemia
Graves' Orbitopathy and Hypercholesterolemia
The investigators have recently observed retrospectively that the occurrence of Graves' Orbitopathy in patients with Graves' disease is less frequent in patients with normal cholesterol levels, in line with another recent…
- Trial name
- GOCol (NCT02721992)
- Testing
- No intervention
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- University of Pisa
TED
A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.
Multicentre, Randomized, Double-blinded, Phase I/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease
- Trial name
- NCT06769984
- Testing
- SCTT11
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Thyroid Eye Disease (TED)
Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
- Trial name
- NCT07262476
- Testing
- MHB018A injection
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Graves Orbitopathy
Immunological Follow-up of Patients With Basedow's Orbitopathy
Graves' disease is characterized by the combination of anti-TSH receptor antibodies (Thyroid-Stimulating Hormone or thyroidotropic hormone), specific to this disease, with inconsistent symptoms such as hyperthyroidism…
- Trial name
- SIPO (NCT04610723)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Montpellier
Exophthalmos, Graves Ophthalmopathy
Exophthalmometry With 3D Face Scanners
This study investigates diagnostic methods to measure eyeball protrusion with a smartphone face scanner compared to the traditional Hertel exophthalmometer.
- Conditions
- Exophthalmos, Graves Ophthalmopathy, Orbital Tumor, Orbital Fractures
- Trial name
- EX3D (NCT04704414)
- Testing
- Exophthalmos measurement
- Where
- Switzerland
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Thyroid Associated Ophthalmopathy
Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated Ophthalmopathy
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter…
- Trial name
- NCT06590220
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Shanghai Changzheng Hospital
Graves Disease, Graves Ophthalmopathy
Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease
This retrospective observational study aims to evaluate the relationship between systemic inflammatory parameters, thyroid autoimmunity markers, and neuroretinal structures in patients with Graves disease.
- Trial name
- NCT07480720
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Elazıg Fethi Sekin Sehir Hastanesi
Thyroid Eye Disease
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
- Trial name
- NCT05524571
- Testing
- Batoclimab
- Where
- 45 sites in United States, Australia and 9 more
- Volunteers
- 86 people
- Sponsor
- Immunovant Sciences GmbH
Graves Ophthalmopathy
Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease
Thyroid eye disease is an autoimmune disorder affecting approximately 50% of individuals with autoimmune thyroid diseases resulting in enlargement of ocular muscles and may lead to congestion of the eyelids and ocular surface…
- Trial name
- CRISEPTED (NCT02339142)
- Testing
- External beam radiotherapy, intravenous corticosteroids (methylprednisolone)
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Dysthyroid Orbitopathy
Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy
The purpose of this protocol is to study orbital structures in Graves´ Disease using multidetector computed tomography and color doppler imaging.
- Trial name
- NCT00665795
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- University of Sao Paulo
Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
The overall objective is to investigate the efficacy, safety and tolerability of TEPEZZA® in participants with chronic (inactive) TED (thyroid eye disease). Approximately 57 participants will be enrolled.
- Trial name
- NCT04583735
- Testing
- TEPEZZA
- Where
- 12 sites in United States
- Volunteers
- 62 people
- Sponsor
- Amgen
Graves Ophthalmopathy
Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves' Orbitopathy
The purpose of the present interventional study is to assess the changes in the therapeutic response, ocular manifestations of Graves' orbitopathy and quality of life during the first year after orbital radiotherapy.
- Trial name
- NCT05775185
- Testing
- Orbital radiotherapy
- Where
- Bulgaria
- Volunteers
- 26 people
- Sponsor
- Medical University of Sofia
Thyroid Eye Disease, TED
Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in…
- Trial name
- SatraGO-1 (NCT05987423)
- Testing
- Satralizumab
- Where
- 46 sites in United States, Argentina and 8 more
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Thyroid Ophthalmopathy
A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease
Primary Objective: To preliminarily evaluate the efficacy of the treatment regimen of HBM9161 680 mg administered subcutaneously weekly and sequentially every other week for 12 weeks in Chinese patients with active moderate to…
- Trial name
- NCT05015127
- Testing
- HBM9161 680 mg qw by q2w from week 13, HBM9161 680 mg qw by q2w from week 7
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
Thyroid-associated Ophthalmopathy
Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections
Thyroid-associated ophthalmopathy (TAO) is an autoimmune process that can affect the orbital and periorbital tissues and the thyroid gland.
- Trial name
- NCT01599273
- Testing
- subconjunctival triamcinolone injection
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yonsei University
Graves' Disease
Post-Radioiodine Graves' Management: The PRAGMA-Study
Thyroid dysfunction following radioiodine for Graves' disease is common, potentially detrimental and avoidable. A variety of clinical strategies are employed in the post-radioiodine era util the patient is on a stable thyroid…
- Trial name
- PRAGMA (NCT01885533)
- Where
- 2 sites in United Kingdom
- Volunteers
- 803 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Thyroid Eye Disease, TED
Multi-modal Medical Images for Extraocular Muscle Fibrosis Assessment
The purpose of this study was to evaluate the elasticity of the extraocular muscles in different stages of thyroid eye disease and to examine the correlation of MRI parameters (native T1 value and ECV) and elasticity for the…
- Trial name
- NCT07056114
- Testing
- The patients with active or inactive TED
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Tianjin Eye Hospital
Thyroid-Associated Ophthalmopathy
99Tc-MDP for Thyroid-Associated Ophthalmopathy
To investigate the efficacy，safety and tolerability of 99Tc-MDP in comparison to Methylprednisolone, in the treatment of participants suffering from active moderate to severe TAO.
- Trial name
- NCT03948191
- Testing
- Methylprednisolone, 99Tc-MDP(99Technetium-Methylenediphosphonate Injection)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Dalian University
Thyroid Eye Disease
B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease
Thyroid eye disease (TED) is an autoimmune inflammation of the orbital tissues that develops in up to 50% of patients with Graves' disease.
- Trial name
- BetTeRTED (NCT02316691)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Pittsburgh